|
1
|
Ferlay J, Shin H, Bray F, Forman D,
Mathers C and Parkin D: GLOBOCAN, 2008 V1. 2, cancer incidence and
mortality Worldwide. IARC Cancer Base. 10:2010.
|
|
2
|
Bray F, Jemal A, Grey N, Ferlay J and
Forman D: Global cancer transitions according to the Human
Development Index (2008–2030): A population-based study. Lancet
Oncol. 13:790–801. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. Ca Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Herbst RS, Heymach JV and Lippman SM: Lung
cancer. N Engl J Med. 359:1367–1380. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Blandin Knight S, Crosbie PA, Balata H,
Chudziak J, Hussell T and Dive C: Progress and prospects of early
detection in lung cancer. Open Biol. 7(pii): 1700702017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
National Center for Chronic Disease
Prevention Health Promotion (US) Office on Smoking Health, . The
health consequences of Smoking-50 years of progress: A report of
the surgeon general. Atlanta (GA): Centers for Disease Control and
Prevention (US); 2014
|
|
7
|
Stockwell HG, Goldman AL, Lyman GH, Noss
CI, Armstrong AW, Pinkham PA, Candelora EC and Brusa MR:
Enviromental tobacco smoke and lung cancer risk in nonsmoking
women. J Natl Cancer Inst. 84:1417–1422. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Boffetta P, Agudo A, Ahrens W, Benhamou E,
Benhamou S, Darby SC, Ferro G, Fortes C, Gonzalez CA, Jöckel KH, et
al: Multicenter case-control study of exposure to environmental
tobacco smoke and lung cancer in europe. J Natl Cancer Inst.
90:1440–1450. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kiyohara C, Wakai K, Mikami H, Sido K,
Ando M and Ohno Y: Risk modification by CYP1A1 and GSTM1
polymorphisms in the association of environmental tobacco smoke and
lung cancer: A case-control study in Japanese nonsmoking women. Int
J Cancer. 107:139–144. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nana-Sinkam SP and Powell CA: Molecular
biology of lung cancer: Diagnosis and management of lung cancer,
3rd edition: American College of Chest Physicians evidence-based
clinical practice guidelines. Chest 143 (5 Suppl). e30S–e39S. 2013.
View Article : Google Scholar
|
|
11
|
Nguyen DX, Chiang AC, Zhang HF, Kim JY,
Kris MG, Ladanyi M, Gerald WL and Massagué J: WNT/TCF Signaling
through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis.
Cell. 138:51–62. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen G, Shukeir N, Potti A, Sircar K,
Aprikian A, Goltzman D and Rabbani SA: Up-regulation of Wnt-1 and
beta-catenin production in patients with advanced metastatic
prostate carcinoma: Potential pathogenetic and prognostic
implications. Cancer. 101:1345–1356. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang WM, Lo Muzio L, Rubini C and Yan G:
Effect of WNT-1 on beta-catenin expression and its relation to
Ki-67 and tumor differentiation in oral squamous cell carcinoma.
Oncol Rep. 13:1095–1099. 2005.PubMed/NCBI
|
|
14
|
Xu X, Sun PL, Li JZ, Jheon S, Lee CT and
Chung JH: Aberrant Wnt1/β-catenin expression is an independent poor
prognostic marker of non-small cell lung cancer after surgery. J
Thorac Oncol. 6:716–724. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
He TC, Sparks AB, Rago C, Hermeking H,
Zawel L, da Costa LT, Morin PJ, Vogelstein B and Kinzler KW:
Identification of c-MYC as a target of the APC pathway. Science.
281:1509–1512. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tetsu O and Mccormick F: Beta-catenin
regulates expression of Cyclin D1 in colon carcinoma cells. Nature.
398:422–426. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hatakeyama S: TRIM family proteins: Roles
in autophagy, immunity, and carcinogenesis. Trends Biochem Sci.
42:297–311. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Reymond A, Meroni G, Fantozzi A, Merla G,
Cairo S, Luzi L, Riganelli D, Zanaria E, Messali S, Cainarca S, et
al: The tripartite motif family identifies cell compartments. EMBO
J. 20:2140–2151. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mallery DL, McEwan WA, Bidgood SR, Towers
GJ, Johnson CM and James LC: Antibodies mediate intracellular
immunity through tripartite motif-containing 21 (TRIM21). Proc Natl
Acad Sci USA. 107:19985–19990. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jiang T, Tang HM, Lu S, Yan DW, Yang YX
and Peng ZH: Up-regulation of tripartite motif-containing 29
promotes cancer cell proliferation and predicts poor survival in
colorectal cancer. Med Oncol. 30:7152013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ren H, Xu Y, Wang Q, Jiang J, Wudumuli,
Hui L, Zhang Q, Zhang X, Wang E, Sun L and Qiu X: E3 ubiquitin
ligase tripartite motif-containing 71 promotes the proliferation of
non-small cell lung cancer through the inhibitor of
kappaB-α/nuclear factor kappaB pathway. Oncotarget. 9:10880–10890.
2017.PubMed/NCBI
|
|
22
|
Yamada Y, Takayama KI, Fujimura T,
Ashikari D, Obinata D, Takahashi S, Ikeda K, Kakutani S, Urano T,
Fukuhara H, et al: A novel prognostic factor TRIM44 promotes cell
proliferation and migration, and inhibits apoptosis in testicular
germ cell tumor. Cancer Sci. 108:32–41. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang Z, Xu C, Zhang X, Huang L, Zheng C,
Chen H, Wang Y, Ju H and Yao Q: TRIM11 upregulation contributes to
proliferation, invasion, and EMT of hepatocellular carcinoma cells.
Oncol Res. 25:691–699. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dükel M, Streitfeld WS, Tang TCC, Backman
LR, Ai L, May WS and Brown KD: The breast cancer tumor suppressor
TRIM29 is expressed via ATM-dependent signaling in response to
hypoxia. J Biol Chem. 291:21541–21552. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Groner AC, Cato L, de Tribolet-Hardy J,
Bernasocchi T, Janouskova H, Melchers D, Houtman R, Cato ACB,
Tschopp P, Gu L, et al: TRIM24 is an oncogenic transcriptional
activator in prostate cancer. Cancer Cell. 29:846–858. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li Y, Ma C, Zhou T, Liu Y, Sun L and Yu Z:
TRIM65 negatively regulates p53 through ubiquitination. Biochem
Biophys Res Commun. 473:278–282. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang XL, Shi WP, Shi HC, Lu SC, Wang K,
Sun C, He JS, Jin WG, Lv XX, Zou H, et al: Knockdown of TRIM65
inhibits lung cancer cell proliferation, migration and invasion: A
therapeutic target in human lung cancer. Oncotarget. 7:81527–81540.
2016.PubMed/NCBI
|
|
28
|
Li H, Zhang Y, Zhang Y, Bai X, Peng Y and
He P: TRIM31 is downregulated in non-small cell lung cancer and
serves as a potential tumor suppressor. Tumour Biol. 35:5747–5752.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Malfavon-Borja R, Sawyer SL, Wu LI,
Emerman M and Malik HS: An evolutionary screen highlights canonical
and noncanonical candidate antiviral genes within the primate TRIM
gene family. Genome Biol Evol. 5:2141–2154. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang Y, Wu SS, Chen XH, Tang ZH, Yu YS
and Zang GQ: Tripartite motif containing 52 (TRIM52) promotes cell
proliferation in hepatitis B virus-associated hepatocellular
carcinoma. Med Sci Monit. 23:5202–5210. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang Y, Tao R, Wu SS, Xu CC, Wang JL,
Chen J, Yu YS, Tang ZH, Chen XH and Zang GQ: TRIM52 up-regulation
in hepatocellular carcinoma cells promotes proliferation, migration
and invasion through the ubiquitination of PPM1A. J Exp Clin Cancer
Res. 37:1162018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang W, Liu L, Li C, Luo N, Chen R, Li L,
Yu F and Cheng Z: TRIM52 plays an oncogenic role in ovarian cancer
associated with NF-κB pathway. Cell Death Dis. 9:9082018.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2-ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hong J, Kang B, Kim A, Hwang S, Ahn J, Lee
S, Kim J, Park JH and Cheon DS: Development of a highly sensitive
real-time one step RT-PCR combined complementary locked primer
technology and conjugated minor groove binder probe. Virol J.
8:3302011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Vogelstein B and Kinzler KW: Cancer genes
and the pathways they control. Nat Med. 10:789–799. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nguyen VN, Mirejovský P, Mirejovský T,
Melínová L and Mandys V: Expression of Cyclin D1, Ki-67 and PCNA in
non-small cell lung cancer: Prognostic significance and comparison
with p53 and bcl-2. Acta Histochem. 102:323–338. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Woods AL, Hall PA, Shepherd NA, Hanby AM,
Waseem NH, Lane DP and Levison DA: The assessment of proliferating
cell nuclear antigen (PCNA)immunostaining in primary
gastrointestinal lymphomas and its relationship to histological
grade, S + G2 + M phase fraction (flow cytometric analysis) and
prognosis. Histopathology. 41:165–171. 2002.PubMed/NCBI
|
|
38
|
Yu CC, Hall PA, Fletcher CD, Camplejohn
RS, Waseem NH, Lane DP and Levison DA: Haemangiopericytomas: The
prognostic value of immunohistochemical staining with a monoclonal
antibody to proliferating cell nuclear antigen (PCNA).
Histopathology. 19:29–33. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tian XH, Hou WJ, Fang Y, Fan J, Tong H,
Bai SL, Chen Q, Xu H and Li Y: XAV939, a tankyrase 1 inhibitior,
promotes cell apoptosis in neuroblastoma cell lines by inhibiting
Wnt/β-catenin signaling pathway. J Exp Clin Cancer Res. 32:1002013.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lu P, Wang Y, Liu X, Wang H, Zhang X, Wang
K, Wang Q and Hu R: Malignant gliomas induce and exploit astrocytic
mesenchymal-like transition by activating canonical Wnt/β-catenin
signaling. Med Oncol. 33:662016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lim JH, Park JW and Chun YS: Human arrest
defective 1 acetylates and activates beta-catenin, promoting lung
cancer cell proliferation. Cancer Res. 66:10677–10682. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Rui X, Hu J, Zhang T, Chao J and Wang HY:
TRIM29 overexpression is associated with poor prognosis and
promotes tumor progression by activating Wnt/β-catenin pathway in
cervical cancer. Oncotarget. 7:28579–28591. 2016.PubMed/NCBI
|
|
43
|
Kim PY, Tan O, Liu B, Trahair T, Liu T,
Haber M, Norris MD, Marshall GM and Cheung BB: High TDP43
expression is required for TRIM16-induced inhibition of cancer cell
growth and correlated with good prognosis of neuroblastoma and
breast cancer patients. Cancer Lett. 374:315–323. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lee OH, Lee J, Lee KH, Woo YM, Kang JH,
Yoon HG, Bae SK, Songyang Z, Oh SH and Choi Y: Role of the focal
adhesion protein TRIM15 in colon cancer development. Biochim
Biophys Acta. 1853:409–421. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Watanabe M and Hatakeyama S: TRIM proteins
and diseases. J Biochem. 161:135–144. 2017.PubMed/NCBI
|
|
46
|
Zhan W, Han T, Zhang C, Xie C, Gan M, Deng
K, Fu M and Wang JB: TRIM59 promotes the proliferation and
migration of non-small cell lung cancer cells by upregulating cell
cycle related proteins. PLoS One. 10:e01425962015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hart T, Chandrashekhar M, Aregger M,
Steinhart Z, Brown KR, Macleod G, Mis M, Zimmermann M,
Fradet-Turcotte A, Sun S, et al: High-resolution CRISPR screens
reveal fitness genes and genotype-specific cancer liabilities.
Cell. 163:1515–1526. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wang T, Birsoy K, Hughes NW, Krupczak KM,
Post Y, Wei JJ, Lander ES and Sabatini DM: Identification and
characterization of essential genes in the human genome. Science.
350:1096–1101. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Peifer M and Polakis P: Wnt signaling in
oncogenesis and embryogenesis-a look outside the nucleus. Science.
287:1606–1609. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
You Z, Saims D, Chen S, Zhang Z, Guttridge
DC, Guan K, Macdougald OA, Brown AM, Evan G, Kitajewski J and Wang
CY: Wnt signaling promotes oncogenic transformation by inhibiting
c-Myc-induced apoptosis. J Cell Biol. 157:429–440. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Brown AM: Wnt signaling in breast cancer:
Have we come full circle? Breast Cancer Res. 3:351–355. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Jiang X, Tan J, Li J, Kivimäe S, Yang X,
Zhuang L, Lee PL, Chan MT, Stanton LW, Liu ET, et al: DACT3 is an
epigenetic regulator of Wnt/beta-catenin signaling in colorectal
cancer and is a therapeutic target of histone modifications. Cancer
Cell. 13:529–541. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Miller DM, Thomas SD, Islam A, Muench D
and Sedoris K: c-Myc and cancer metabolism. Clin Cancer Res.
18:5546–5553. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Hall M and Peters G: Genetic alterations
of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human
cancer. Adv Cancer Res. 68:67–108. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Yu Q, Geng Y and Sicinski P: Specific
protection against breast cancers by Cyclin D1 ablation. Nature.
411:1017–1021. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Lukas J, Bartkova J, Rohde M, Strauss M
and Bartek J: Cyclin D1 is dispensable for G1 control in
retinoblastoma gene-deficient cells independently of cdk4 activity.
Mol Cell Biol. 15:2600–2611. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Griffey SM, Kraegel SA and Madewell BR:
Proliferation indices in spontaneous canine lung cancer:
Proliferating cell nuclear antigen (PCNA), Ki-67 (MIB1) and mitotic
counts. J Comp Pathol. 120:321–332. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Celis JE and Celis A: Cell cycle-dependent
variations in the distribution of the nuclear protein cyclin
proliferating cell nuclear antigen in cultured cells: Subdivision
of S phase. Proc Natl Acad Sci USA. 82:3262–3266. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Bravo R, Frank R, Blundell PA and
Macdonaldbravo H: Cyclin/PCNA is the auxiliary protein of DNA
polymerase-delta. Nature. 326:515–517. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Benke S, Agerer B, Haas L, Stöger M,
Lercher A, Gabler L, Kiss I, Scinicariello S, Berger W, Bergthaler
A, et al: Human tripartite motif protein 52 is required for cell
context-dependent proliferation. Oncotarget. 9:13565–13581. 2018.
View Article : Google Scholar : PubMed/NCBI
|
